About: http://data.cimple.eu/news-article/3c20b989e21fdefe4f8574cfb043f18c89fd07f3c5a1b382d3ec176e     Goto   Sponge   NotDistinct   Permalink

An Entity of Type : schema:NewsArticle, within Data Space : data.cimple.eu associated with source document(s)

AttributesValues
rdf:type
schema:articleBody
  • French authorities are set to rule that under 55s who received a first injection of the AstraZeneca Covid-19 vaccine can be given a jab from a different producer for their second dose, Health Minister Olivier Veran said on Friday. France's national health authority HAS last month said that the AstraZeneca vaccine should only be given to those aged 55 and over, due to the reports of potentially deadly blood clots in a very small number of those younger people vaccinated. Officials in France initially said that those given the AstraZeneca jab in a first dose should go ahead with the second jab even if aged under 55, but Veran indicated that the HAS would change the advice. "This will normally be confirmed today, it is totally logical," said Veran, with the HAS due to give a news conference at 0800 GMT. France has been injecting healthworkers as a priority group in the vaccination drive, meaning that many younger people have already received the AstraZeneca jab due to their work. As Veran noted, they included the minister himself, a neurologist aged 41, who was given the AstraZeneca vaccine live on television on February 8. "It is completely consistent to say that we do not recommend the AstraZeneca vaccine to people under 55 years of age while we learn more," he said. "Therefore, if you have received a first injection and are under 55 years old, you will be offered another vaccine 12 weeks after the first injection," he added. Europe's medicines regulator said this week the AstraZeneca vaccine could cause very rare blood clots among some recipients, prompting several countries to to scale up restrictions on the jab. There are several clinical trials underway looking at the efficacy of combining two types of coronavirus vaccine -- testing the technique known as heterologous prime-boosting. Experts say the theory is sound and, as with some other diseases, it could help convey effective immunity. "Based on previous studies which combine different vaccine types, a combination of the AZ and Pfizer vaccines is likely to be safe but it's important that this is tested in the context of a clinical vaccine trial," said Helen Fletcher, professor of Immunology at the London School of Hygiene and Tropical Medicine. pr-sjw/wdb
schema:headline
  • French under-55s given AZ jab to get different 2nd dose
schema:mentions
schema:author
schema:datePublished
http://data.cimple...sPoliticalLeaning
http://data.cimple...logy#hasSentiment
http://data.cimple...readability_score
http://data.cimple...tology#hasEmotion
http://data.cimple...entionsConspiracy
Faceted Search & Find service v1.16.115 as of Oct 09 2023


Alternative Linked Data Documents: ODE     Content Formats:   [cxml] [csv]     RDF   [text] [turtle] [ld+json] [rdf+json] [rdf+xml]     ODATA   [atom+xml] [odata+json]     Microdata   [microdata+json] [html]    About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data] Valid XHTML + RDFa
OpenLink Virtuoso version 07.20.3238 as of Jul 16 2024, on Linux (x86_64-pc-linux-musl), Single-Server Edition (126 GB total memory, 2 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software